Short Interest in Citius Oncology, Inc. (NASDAQ:CTOR) Expands By 51.2%

Citius Oncology, Inc. (NASDAQ:CTOR) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 983,877 shares, an increase of 51.2% from the December 15th total of 650,544 shares. Approximately 1.2% of the company’s shares are sold short. Based on an average trading volume of 727,864 shares, the days-to-cover ratio is presently 1.4 days. Based on an average trading volume of 727,864 shares, the days-to-cover ratio is presently 1.4 days. Approximately 1.2% of the company’s shares are sold short.

Institutional Trading of Citius Oncology

Hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC acquired a new stake in Citius Oncology during the third quarter valued at $36,000. Bank of America Corp DE grew its position in shares of Citius Oncology by 5,256.9% during the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock valued at $37,000 after acquiring an additional 8,411 shares during the period. Arkadios Wealth Advisors purchased a new position in shares of Citius Oncology in the 2nd quarter valued at about $51,000. IFP Advisors Inc increased its stake in shares of Citius Oncology by 49.5% in the 3rd quarter. IFP Advisors Inc now owns 33,215 shares of the company’s stock valued at $67,000 after purchasing an additional 11,000 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Citius Oncology by 179.0% in the 2nd quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock worth $249,000 after purchasing an additional 36,758 shares during the period. 70.52% of the stock is owned by hedge funds and other institutional investors.

Citius Oncology Stock Performance

NASDAQ:CTOR traded down $0.01 during mid-day trading on Friday, hitting $1.07. The company’s stock had a trading volume of 45,530 shares, compared to its average volume of 265,222. The business’s fifty day moving average is $1.19 and its two-hundred day moving average is $1.78. The stock has a market cap of $90.74 million, a price-to-earnings ratio of -3.15 and a beta of 3.09. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.56 and a quick ratio of 0.11. Citius Oncology has a 1 year low of $0.55 and a 1 year high of $6.19.

Citius Oncology (NASDAQ:CTOR) last issued its quarterly earnings data on Tuesday, December 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06).

Wall Street Analysts Forecast Growth

A number of research analysts have commented on CTOR shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Oncology in a research report on Monday, December 22nd. Maxim Group raised shares of Citius Oncology from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a research report on Tuesday, September 23rd. Finally, Citigroup raised Citius Oncology from a “hold” rating to a “buy” rating in a research report on Tuesday, September 23rd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $6.00.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.